

Inventors: Huse and Glaser
Serial No.: 09/016,061
Filed: January 30, 1998
Page 2

81. (New) The antibody of claim 80, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

82. (New) An antibody, or functional fragment thereof, comprising a V_H CDR2 selected from the group consisting of the CDRs referenced as SEQ ID NO:54, SEQ ID NO:56 and SEQ ID NO:58.

83. (New) The antibody of claim 82, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

84. (New) An antibody, or functional fragment thereof, comprising a V_H CDR3 selected from the group consisting of the CDRs referenced as SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:94, SEQ ID NO:96; SEQ ID NO:98 and SEQ ID NO:100.

85. (New) The antibody of claim 84, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

86. (New) An antibody, or functional fragment thereof, comprising a V_L CDR1 referenced as SEQ ID NO:82.

B1
Cont.

Inventors: Huse and Glaser
Serial No.: 09/016,061
Filed: January 30, 1998
Page 3

87. (New) The antibody of claim 86, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

88. (New) An antibody, or functional fragment thereof, comprising a V_L CDR2 referenced as SEQ ID NO:84.

89. (New) The antibody of claim 88, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

90. (New) An antibody, or functional fragment thereof, comprising a V_L CDR3 selected from the group consisting of the CDRs referenced as SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90 and SEQ ID NO:92.

B1
Cont.
91. (New) The antibody of claim 90, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

92. (New) An antibody, or functional fragment thereof, comprising the combination of CDRs selected from the group consisting of:

the V_L CDR1 referenced as SEQ ID NO:82 and the V_H CDR3 referenced as SEQ ID NO:68;

the V_L CDR1 referenced as SEQ ID NO:82, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:68;

Inventors: Huse and Glaser
Serial No.: 09/016,061
Filed: January 30, 1998
Page 4

the V_L CDR1 referenced as SEQ ID NO:82, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:72;

the V_L CDR1 referenced as SEQ ID NO:82, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:70;

the V_L CDR1 referenced as SEQ ID NO:82 and the V_H CDR3 referenced as SEQ ID NO:72;

the V_L CDR3 referenced as SEQ ID NO:86, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:68;

the V_L CDR3 referenced as SEQ ID NO:90 and V_H CDR3 referenced as SEQ ID NO:68; and

the V_L CDR3 referenced as SEQ ID NO:90, the V_H CDR2 referenced as SEQ ID NO:56 and V_H CDR3 referenced as SEQ ID NO:68.

B1
cont.
93. (New) The antibody of claims 92, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

94. (New) An antibody, or functional fragment thereof, comprising the combination of CDRs selected from the group consisting of:

the V_L CDR1 referenced as SEQ ID NO:82, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:94;

Inventors: Huse and Glaser
Serial No.: 09/016,061
Filed: January 30, 1998
Page 5

the V_L CDR3 referenced as SEQ ID NO:90, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:94;

the V_L CDR3 referenced as SEQ ID NO:90, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:96;

the V_L CDR3 referenced as SEQ ID NO:90 and the V_H CDR3 referenced as SEQ ID NO:94;

the V_L CDR3 referenced as SEQ ID NO:90 and the V_H CDR3 referenced as SEQ ID NO:98; and

the V_L CDR3 referenced as SEQ ID NO:90, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:100.

95. (New) The antibody of claims 94, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

96. (New) An antibody, or functional fragment thereof, comprising the combination of CDRs selected from the group consisting of:

the V_L CDR1 referenced as SEQ ID NO:82 and the V_H CDR3 referenced as SEQ ID NO:68;

the V_L CDR1 referenced as SEQ ID NO:82, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:68;

31
Cont.

Inventors: Huse and Glaser
Serial No.: 09/016,061
Filed: January 30, 1998
Page 6

the V_L CDR1 referenced as SEQ ID NO:82, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:72;

the V_L CDR1 referenced as SEQ ID NO:82, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:70;

the V_L CDR1 referenced as SEQ ID NO:82 and the V_H CDR3 referenced as SEQ ID NO:72;

the V_L CDR3 referenced as SEQ ID NO:86, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:68;

the V_L CDR3 referenced as SEQ ID NO:90, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:94;

the V_L CDR3 referenced as SEQ ID NO:90 and V_H CDR3 referenced as SEQ ID NO:68;

the V_L CDR3 referenced as SEQ ID NO:90, the V_H CDR2 referenced as SEQ ID NO:56 and V_H CDR3 referenced as SEQ ID NO:68;

the V_L CDR1 referenced as SEQ ID NO:82, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:94;

the V_L CDR3 referenced as SEQ ID NO:90, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:96;

the V_L CDR3 referenced as SEQ ID NO:90 and the V_H CDR3 referenced as SEQ ID NO:94;

the V_L CDR3 referenced as SEQ ID NO:90 and the V_H CDR3 referenced as SEQ ID NO:98; and

B
Cont.

Inventors: Huse and Glaser
Serial No.: 09/016,061
Filed: January 30, 1998
Page 7

the V_L CDR3 referenced as SEQ ID NO:90, the V_H CDR2 referenced as SEQ ID NO:56 and the V_H CDR3 referenced as SEQ ID NO:100.

97. (New) The antibody of claim 96, wherein said functional fragment is selected from the group consisting of Fv, Fab, $F(ab)_2$ and scFV.

98. (New) A method of inhibiting a function of $\alpha_v\beta_3$ comprising contacting $\alpha_v\beta_3$ with the enhanced LM609 grafted antibody of claim 56, or a functional fragment thereof, under conditions which allow binding of said enhanced LM609 grafted antibody to $\alpha_v\beta_3$.

99. (New) The method of claim 98, wherein said functional fragment is selected from the group consisting of Fv, Fab, $F(ab)_2$ and scFV.

100. (New) The method of claim 98, wherein said function of $\alpha_v\beta_3$ is binding of $\alpha_v\beta_3$ to a ligand.

101. (New) The method of claim 98, wherein said function of $\alpha_v\beta_3$ is integrin mediated signal transduction.

102. (New) A method of treating an $\alpha_v\beta_3$ -mediated disease comprising administering an effective amount of the enhanced LM609 grafted antibody of claim 56, or a functional fragment thereof, under conditions which allow binding to $\alpha_v\beta_3$.

B1
Cont..